Health Catalyst Stock Alpha and Beta Analysis
| HCAT Stock | USD 4.14 0.03 0.73% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Health Catalyst. It also helps investors analyze the systematic and unsystematic risks associated with investing in Health Catalyst over a specified time horizon. Remember, high Health Catalyst's alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Health Catalyst's market risk premium analysis include:
Beta 1.1 | Alpha (0.84) | Risk 3.79 | Sharpe Ratio (0.26) | Expected Return (0.99) |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Health |
Health Catalyst Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Health Catalyst market risk premium is the additional return an investor will receive from holding Health Catalyst long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Health Catalyst. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Health Catalyst's performance over market.| α | -0.84 | β | 1.10 |
Health Catalyst expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Health Catalyst's Buy-and-hold return. Our buy-and-hold chart shows how Health Catalyst performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Health Catalyst Market Price Analysis
Market price analysis indicators help investors to evaluate how Health Catalyst stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Health Catalyst shares will generate the highest return on investment. By understating and applying Health Catalyst stock market price indicators, traders can identify Health Catalyst position entry and exit signals to maximize returns.
Health Catalyst Return and Market Media
The median price of Health Catalyst for the period between Sun, Dec 15, 2024 and Sat, Mar 15, 2025 is 5.7 with a coefficient of variation of 20.27. The daily time series for the period is distributed with a sample standard deviation of 1.23, arithmetic mean of 6.07, and mean deviation of 1.05. The Stock received substential amount of media coverage during this period. Price Growth (%) |
| Timeline |
1 | Disposition of 6442 shares by Linda Llewelyn of Health Catalyst at 7.8848 subject to Rule 16b-3 | 12/16/2024 |
2 | Disposition of 4500 shares by Gallagher Duncan of Health Catalyst at 6.9298 subject to Rule 16b-3 | 12/30/2024 |
3 | Disposition of 2500 shares by Benjamin Landry of Health Catalyst at 7.5182 subject to Rule 16b-3 | 01/06/2025 |
4 | Health Catalyst to Acquire Upfront Healthcare Services - Yahoo Finance | 01/14/2025 |
5 | Disposition of 5209 shares by Daniel LeSueur of Health Catalyst at 5.7607 subject to Rule 16b-3 | 02/06/2025 |
6 | Beyond The Numbers 8 Analysts Discuss Health Catalyst Stock - Benzinga | 02/11/2025 |
7 | Disposition of 6441 shares by Linda Llewelyn of Health Catalyst at 5.4266 subject to Rule 16b-3 | 02/18/2025 |
8 | Acquisition by Daniel LeSueur of 145000 shares of Health Catalyst subject to Rule 16b-3 | 02/20/2025 |
9 | Health Catalysts Q4 Earnings Results Revenue In Line With Expectations, Growth To Accelerate Next Year | 02/26/2025 |
10 | Compared to Estimates, Health Catalyst Q4 Earnings A Look at Key Metrics | 02/27/2025 |
11 | Disposition of 16902 shares by Daniel LeSueur of Health Catalyst at 4.5161 subject to Rule 16b-3 | 03/05/2025 |
12 | Disposition of 13827 shares by Benjamin Landry of Health Catalyst at 4.5462 subject to Rule 16b-3 | 03/06/2025 |
13 | Acquisition by Kevin Freeman of 140000 shares of Health Catalyst subject to Rule 16b-3 | 03/11/2025 |
14 | Daniel Lesueur Sells 16,902 Shares of Health Catalyst, Inc. Stock | 03/12/2025 |
About Health Catalyst Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Health or other stocks. Alpha measures the amount that position in Health Catalyst has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2021 | 2023 | 2025 (projected) | Interest Debt Per Share | 4.65 | 4.54 | 2.78 | Revenue Per Share | 5.09 | 5.25 | 4.03 |
Health Catalyst Upcoming Company Events
As portrayed in its financial statements, the presentation of Health Catalyst's financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Health Catalyst's leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Health Catalyst's public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Health Catalyst. Please utilize our Beneish M Score to check the likelihood of Health Catalyst's management manipulating its earnings.
| 27th of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 27th of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Health Catalyst
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Additional Tools for Health Stock Analysis
When running Health Catalyst's price analysis, check to measure Health Catalyst's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Health Catalyst is operating at the current time. Most of Health Catalyst's value examination focuses on studying past and present price action to predict the probability of Health Catalyst's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Health Catalyst's price. Additionally, you may evaluate how the addition of Health Catalyst to your portfolios can decrease your overall portfolio volatility.